ACHE and Alzheimer disease: Utilizing the endogenous nature of how the existing AD drugs cross the blood brain barrier might facilitate the design and development of HDAC inhibitors, or even two-target drugs targeting AChE and HDACs to achieve a combined therapeutic effect on AD.